Dyslipidemia Drugs Sales Market Exhibits a Lucrative Growth Potential during 2020-2025 | Sanofi, GSK, AstraZeneca, Merck, Pfizer, Amgen, Bristol-Myers Squibb, Eli Lilly, Lupin

Global Dyslipidemia Drugs Sales Market Synopsis:

The exclusive research report on the Global Dyslipidemia Drugs Sales Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global Dyslipidemia Drugs Sales Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.

Some of the most important key factors driving the growth of the Global Dyslipidemia Drugs Sales Market are rapid growth in the disease awareness through promotional activities, and increasing prevalence of population with cholesterol and triglyceride abnormalities.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/273333 .

Significant points in table of contents: Market Definition, Market Overview, Business Introduction, Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation (Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost Analysis, and Conclusion. The Dyslipidemia Drugs Sales Market is segmented based on Product, source, application and Regions. On the basis of product, the market is sub-segmented.

According to the geographic analysis, North America market is the prime contributor to the Dyslipidemia Drugs Sales Market owing to favorable government approval policies coupled with increasing incidence of dyslipidemia in North American countries such as the U.S. and Canada. The organization also stated that the prevalence of dyslipidemia is rapidly increasing among the patient population in the U.S. Additionally, increasing obese and diabetic population in the U.S. and Canada further augments the dyslipidemia cases.

Top Major Key Players in the Global Dyslipidemia Drugs Sales Market:

1 AstraZeneca

2 Merck

3 Pfizer

4 Sanofi

5 Alnylam Pharmaceuticals

6 Amarin Corporation

7 Amgen

8 Bristol-Myers Squibb

9 Catabasis Pharmaceuticals

10 Cerenis

11 Cipla

12 CJ HealthCare

13 CKD Bio

14 Daewoong Pharmaceutical

15 Daiichi Sankyo

16 Eli Lilly

17 Esperion Therapeutics

18 GlaxoSmithKline

19 JW Pharmaceuticals

20 Kadmon Pharmaceuticals

21 Lupin Pharmaceuticals and More………………….

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Dyslipidemia Drugs Sales Market Report 2020” @ https://www.businessindustryreports.com/buy-now/273333/single .

Product Type Segmentation

1 Statins

2 Cholesterol absorption inhibitors

3 Dyslipidemia injectable

Industry Segmentation

1 Hospitals and Clinics

2 Medical Laboratories

3 Drug Stores

Top Medical Industry News:

Sanofi (July 02, 2020) - Sanofi and Regeneron provide update on Kevzara (sarilumab) Phase 3 U.S. trial in COVID-19 patients - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Phase 3 trial of Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).

Minor positive trends were observed in the primary pre-specified analysis group (critical patients on Kevzara 400 mg who were mechanically ventilated at baseline) that did not reach statistical significance and these were countered by negative trends in a subgroup of critical patients who were not mechanically ventilated at baseline1. In the primary analysis group, adverse events were experienced by 80% of Kevzara patients and 77% of placebo patients. Serious adverse events that occurred in at least 3% of patients and more frequently among Kevzara patients were multi organ dysfunction syndrome (6% Kevzara, 5% placebo) and hypotension (4% Kevzara, 3% placebo).

Based on the results, the U.S.-based trial has been stopped, including in a second cohort of patients who received a higher dose of Kevzara (800 mg). Detailed results will be submitted to a peer-reviewed publication later this year.

The primary analysis group included 194 patients who were critically ill with COVID-19 and receiving mechanical ventilation at the time of enrolment. The primary endpoint assessed the percentage of patients who achieved at least a 1-point change from baseline on a 7-point scale, which consisted of 1) death; 2) hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4) hospitalized, requiring supplemental oxygen; 5) hospitalized, not requiring supplemental oxygen – requiring ongoing medical care (COVID-19 related or otherwise); 6) hospitalized, not requiring supplemental oxygen – no longer requires ongoing medical care; 7) discharged from hospital. A second cohort, which was partially recruited (n=27), compared Kevzara 800 mg versus placebo.

The Kevzara trial was designed after a small (n=21), single-arm study in China (Xu et al) among mostly severe, febrile hospitalized COVID-19 patients found elevated IL-6 levels and suggested that inhibiting this pathway with the IL-6 blocker tocilizumab rapidly reduced fever and improved oxygenation in severe patients, allowing for successful hospital discharge. The Phase 3 Kevzara trial was designed to evaluate this hypothesis in a large, placebo-controlled trial. The trial has been funded in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under OT number: HHSO100201700020C.

A separate Sanofi-led trial outside of the U.S. in hospitalized patients with severe and critical COVID-19 using a different dosing regimen is ongoing. The same Independent Data Monitoring Committee (IDMC) is overseeing both the Regeneron-led U.S. trial and the Sanofi-led trial outside of U.S., which has recommended that the trial outside of the U.S. continue. The companies expect to report results in Q3 2020.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/273333 .

Major Points in Table of Contents:

Global Dyslipidemia Drugs Sales Market Report 2020

1 Dyslipidemia Drugs Sales Product Definition

2 Global Dyslipidemia Drugs Sales Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Dyslipidemia Drugs Sales Shipments

2.2 Global Manufacturer Dyslipidemia Drugs Sales Business Revenue

2.3 Global Dyslipidemia Drugs Sales Market Overview

2.4 COVID-19 Impact on Dyslipidemia Drugs Sales Industry

3 Manufacturer Dyslipidemia Drugs Sales Business Introduction

3.1 AstraZeneca Dyslipidemia Drugs Sales Business Introduction

3.2 Merck Dyslipidemia Drugs Sales Business Introduction

3.3 Pfizer Dyslipidemia Drugs Sales Business Introduction

3.4 Sanofi Dyslipidemia Drugs Sales Business Introduction

3.5 Alnylam Pharmaceuticals Dyslipidemia Drugs Sales Business Introduction

3.6 Amarin Corporation Dyslipidemia Drugs Sales Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.